Lisata Therapeutics (NASDAQ:LSTA) Earns “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Lisata Therapeutics (NASDAQ:LSTA) in a report issued on Wednesday morning, Benzinga reports. HC Wainwright currently has a $15.00 price objective on the stock.

Lisata Therapeutics Price Performance

LSTA opened at $3.18 on Wednesday. Lisata Therapeutics has a 12-month low of $1.99 and a 12-month high of $3.83. The stock has a market capitalization of $26.42 million, a PE ratio of -1.29 and a beta of 1.21. The firm’s fifty day moving average price is $3.11 and its 200 day moving average price is $3.11.

Lisata Therapeutics (NASDAQ:LSTA) last issued its earnings results on Monday, August 12th. The company reported ($0.61) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.14. During the same quarter last year, the business posted ($0.50) earnings per share. On average, equities research analysts forecast that Lisata Therapeutics will post -2.97 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lisata Therapeutics

A hedge fund recently raised its stake in Lisata Therapeutics stock. Dimensional Fund Advisors LP boosted its holdings in Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 48.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,336 shares of the company’s stock after purchasing an additional 5,639 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.21% of Lisata Therapeutics worth $60,000 at the end of the most recent quarter. 8.94% of the stock is currently owned by institutional investors and hedge funds.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.